{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:07:22Z","timestamp":1791493642904,"version":"4.3.4"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"State Key Laboratory of Ultrasound in Medicine and Engineering","award":["2020KFKT016"],"award-info":[{"award-number":["2020KFKT016"]}]},{"name":"State Key Laboratory of Ultrasound in Medicine and Engineering","award":["2022KFKT011"],"award-info":[{"award-number":["2022KFKT011"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p>Given the unique features of the liver, it is necessary to combine immunotherapy with other therapies to improve its efficacy in patients of advanced cancer with liver metastases (LM). High-intensity focused ultrasound (HIFU) ablation is now widely used in clinical practice and can enhanced immune benefits. The study is intended to prospectively evaluate the safety and clinical feasibility of HIFU ablation in combination with systemic immunotherapy for patients with liver metastases.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The study enrolled 14 patients with LM who received ultrasound-guided HIFU ablation combined with immune checkpoint inhibitors (ICIs) such as anti-programmed cell death protein 1 (anti-PD-1 agents manufactured in China) at Mianyang Central Hospital. Patients were followed up for adverse events (AEs) during the trial, using the CommonTerminology Criteria for Adverse Events v5.0(CTCAE v5.0) as the standard. Tumour response after treatment was assessed using computerized tomography.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The 14 patients (age range, 35\u201384 years) underwent HIFU ablation at 19 metastatic sites and systemic immunotherapy. The mean lesion volume was 179.9 cm3 (maximum: 733.1 cm3). Median follow-up for this trial was 9 months (range: 3\u201321) months. The study is clinically feasible and acceptable to patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This prospective study confirmed that HIFU combined with immunotherapy is clinically feasible and safe for treating liver metastases.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0306595","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T17:22:32Z","timestamp":1720200152000},"page":"e0306595","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["High-intensity focused ultrasound ablation combined with immunotherapy for treating liver metastases: A prospective non-randomized trial"],"prefix":"10.1371","volume":"19","author":[{"given":"Xiyue","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binwei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongbiao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6348-0636","authenticated-orcid":true,"given":"Xiaobo","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"issue":"4","key":"pone.0306595.ref001","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","article-title":"Cancer metastasis: building a framework","volume":"127","author":"GP Gupta","year":"2006","journal-title":"Cell"},{"issue":"1","key":"pone.0306595.ref002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.suronc.2007.04.008","article-title":"Epidemiology of colorectal liver metastases","volume":"16","author":"DC McMillan","year":"2007","journal-title":"Surg Oncol"},{"issue":"15","key":"pone.0306595.ref003","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1177\/1535370216658144","article-title":"Liver metastases: Microenvironments and ex-vivo models","volume":"241","author":"AM Clark","year":"2016","journal-title":"Exp Biol Med (Maywood)"},{"key":"pone.0306595.ref004","doi-asserted-by":"crossref","first-page":"101760","DOI":"10.1016\/j.canep.2020.101760","article-title":"Epidemiology of liver metastases","volume":"67","author":"SR Horn","year":"2020","journal-title":"Cancer Epidemiol"},{"issue":"10","key":"pone.0306595.ref005","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/cncr.32789","article-title":"Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990\u20132017","volume":"126","author":"Z Liu","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"pone.0306595.ref006","doi-asserted-by":"crossref","first-page":"931","DOI":"10.5858\/2008-132-931-MPOCRF","article-title":"Metastatic patterns of cancers: results from a large autopsy study","volume":"132","author":"G Disibio","year":"2008","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"pone.0306595.ref007","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jacr.2015.12.001","article-title":"ACR Appropriateness Criteria Radiologic Management of Hepatic Malignancy","volume":"13","author":"BE Kouri","year":"2016","journal-title":"J Am Coll Radiol"},{"issue":"20","key":"pone.0306595.ref008","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.3748\/wjg.v20.i20.6113","article-title":"Role of surgery in colorectal cancer liver metastases","volume":"20","author":"\u00d6 Akg\u00fcl","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"3","key":"pone.0306595.ref009","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ejcts.2008.05.016","article-title":"Postrecurrence survival in patients with stage I non-small cell lung cancer","volume":"34","author":"T Nakagawa","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"issue":"2","key":"pone.0306595.ref010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/GCO.0000000000000257","article-title":"Targeting the programmed cell death-1 pathway in breast and ovarian cancer","volume":"28","author":"LA Emens","year":"2016","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"1","key":"pone.0306595.ref011","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-018-0349-3","article-title":"Current landscape and future of dual anti-CTLA4 and PD-1\/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)","volume":"6","author":"YK Chae","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"10","key":"pone.0306595.ref012","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/phar.1643","article-title":"Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy","volume":"35","author":"NM La-Beck","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"10064","key":"pone.0306595.ref013","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"AV Balar","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"19","key":"pone.0306595.ref014","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"RJ Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"6377","key":"pone.0306595.ref015","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"D Miao","year":"2018","journal-title":"Science"},{"issue":"10","key":"pone.0306595.ref016","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.6004\/jnccn.2017.7036","article-title":"Urothelial carcinoma of the bladder and the rise of immunotherapy","volume":"15","author":"DD Chism","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"issue":"3","key":"pone.0306595.ref017","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo","volume":"194","author":"R Das","year":"2015","journal-title":"J Immunol"},{"issue":"9","key":"pone.0306595.ref018","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"L Chen","year":"2015","journal-title":"J Clin Invest"},{"issue":"1","key":"pone.0306595.ref019","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1186\/s12885-019-6073-7","article-title":"Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy","volume":"19","author":"MA Bilen","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"pone.0306595.ref020","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.ymthe.2021.04.015","article-title":"Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus","volume":"29","author":"PK Wan","year":"2021","journal-title":"Mol Ther"},{"issue":"52","key":"pone.0306595.ref021","doi-asserted-by":"crossref","first-page":"eaba0759","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"JC Lee","year":"2020","journal-title":"Sci Immunol"},{"issue":"1","key":"pone.0306595.ref022","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"J Yu","year":"2021","journal-title":"Nat Med"},{"key":"pone.0306595.ref023","doi-asserted-by":"crossref","first-page":"994276","DOI":"10.3389\/fonc.2022.994276","article-title":"Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis","volume":"12","author":"RY Wu","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"pone.0306595.ref024","doi-asserted-by":"crossref","first-page":"1746113","DOI":"10.1080\/2162402X.2020.1746113","article-title":"liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials","volume":"9","author":"S Li","year":"2020","journal-title":"Oncoimmunology"},{"issue":"7","key":"pone.0306595.ref025","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1470-2045(09)70082-8","article-title":"Systemic effects of local radiotherapy","volume":"10","author":"SC Formenti","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7","key":"pone.0306595.ref026","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1158\/0008-5472.CAN-09-2982","article-title":"Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy","volume":"70","author":"T Takeshima","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"pone.0306595.ref027","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"L Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"pone.0306595.ref028","doi-asserted-by":"crossref","first-page":"108111","DOI":"10.1016\/j.pharmthera.2022.108111","article-title":"The immune modifying effects of chemotherapy and advances in chemo-immunotherapy","volume":"236","author":"DR Principe","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"11","key":"pone.0306595.ref029","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC","volume":"16","author":"MA Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"3","key":"pone.0306595.ref030","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"SGC Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"pone.0306595.ref031","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"W Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"pone.0306595.ref032","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1158\/0008-5472.CAN-03-3949","article-title":"In situ tumor ablation creates an antigen source for the generation of antitumor immunity","volume":"64","author":"MH den Brok","year":"2004","journal-title":"Cancer Res"},{"key":"pone.0306595.ref033","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1479-5876-5-34","article-title":"Investigation of HIFU-induced anti-tumor immunity in a murine tumor model","volume":"5","author":"Z Hu","year":"2007","journal-title":"J Transl Med"},{"issue":"28","key":"pone.0306595.ref034","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.3748\/wjg.v16.i28.3584","article-title":"Enhancement of antitumor vaccine in ablated hepatocellular carcinoma by high-intensity focused ultrasound","volume":"16","author":"Y Zhang","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"8","key":"pone.0306595.ref035","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.ultrasmedbio.2012.03.009","article-title":"High-intensity focused ultrasound tumor ablation activates autologous tumor-specific cytotoxic T lymphocytes","volume":"38","author":"JZ Xia","year":"2012","journal-title":"Ultrasound Med Biol"},{"issue":"6","key":"pone.0306595.ref036","doi-asserted-by":"crossref","first-page":"e90521","DOI":"10.1172\/jci.insight.90521","article-title":"Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols","volume":"2","author":"MT Silvestrini","year":"2017","journal-title":"JCI Insight"},{"issue":"2","key":"pone.0306595.ref037","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00262-016-1891-9","article-title":"Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies","volume":"66","author":"RJ van den Bijgaart","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"pone.0306595.ref038","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc1591","article-title":"High-intensity focused ultrasound in the treatment of solid tumours","volume":"5","author":"JE Kennedy","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"pone.0306595.ref039","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11684-010-0092-8","article-title":"High-intensity focused ultrasound tumor ablation: review of ten years of clinical experience","volume":"4","author":"L Zhang","year":"2010","journal-title":"Front Med China"},{"issue":"4","key":"pone.0306595.ref040","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4103\/0973-1482.77064","article-title":"High intensity focused ultrasound ablation: a new therapeutic option for solid tumors","volume":"6","author":"F Orsi","year":"2010","journal-title":"J Cancer Res Ther"},{"issue":"11","key":"pone.0306595.ref041","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s00330-016-4222-9","article-title":"First clinical experience with a dedicated MRI-guided high-intensity focused ultrasound system for breast cancer ablation","volume":"26","author":"LG Merckel","year":"2016","journal-title":"Eur Radiol"},{"key":"pone.0306595.ref042","doi-asserted-by":"crossref","first-page":"1038347","DOI":"10.3389\/fimmu.2022.1038347","article-title":"Mechanical high-intensity focused ultrasound creates unique tumor debris enhancing dendritic cell-induced T cell activation","volume":"13","author":"RJE van den Bijgaart","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"pone.0306595.ref043","doi-asserted-by":"crossref","first-page":"W245","DOI":"10.2214\/AJR.09.3321","article-title":"High-intensity focused ultrasound ablation: effective and safe therapy for solid tumors in difficult locations et al. High-intensity focused ultrasound ablation: effective and safe therapy for solid tumors in difficult locations","volume":"195","author":"F Orsi","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"967","key":"pone.0306595.ref044","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1259\/bjr\/27118953","article-title":"High-intensity focused ultrasound ablation of liver tumours: can radiological assessment predict the histological response?","volume":"81","author":"TA Leslie","year":"2008","journal-title":"Br J Radiol"},{"issue":"3","key":"pone.0306595.ref045","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/02656730802641949","article-title":"Preliminary experience using high intensity focused ultrasound for treating liver metastasis from colon and stomach cancer","volume":"25","author":"MY Park","year":"2009","journal-title":"Int J Hyperthermia"},{"issue":"5","key":"pone.0306595.ref046","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s11547-011-0634-4","article-title":"High-intensity focused ultrasound (HIFU) in patients with solid malignancies: evaluation of feasibility, local tumour response and clinical results","volume":"116","author":"G Orgera","year":"2011","journal-title":"Radiol Med"},{"issue":"1018","key":"pone.0306595.ref047","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1259\/bjr\/56737365","article-title":"High-intensity focused ultrasound treatment of liver tumours: post-treatment MRI correlates well with intra-operative estimates of treatment volume","volume":"85","author":"T Leslie","year":"2012","journal-title":"Br J Radiol"},{"issue":"137","key":"pone.0306595.ref048","first-page":"140","article-title":"High intensity focused ultrasound ablation for patients with inoperable liver cancer","volume":"62","author":"L Chen","year":"2015","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"pone.0306595.ref049","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ultrasmedbio.2007.07.013","article-title":"Changes in circulating immunosuppressive cytokine levels of cancer patients after high intensity focused ultrasound treatment","volume":"34","author":"Q Zhou","year":"2008","journal-title":"Ultrasound Med Biol"},{"issue":"3","key":"pone.0306595.ref050","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jum.16053","article-title":"Combination of Focused Ultrasound, Immunotherapy, and Chemotherapy: New Perspectives in Breast Cancer Therapy","volume":"42","author":"M Dahan","year":"2023","journal-title":"J Ultrasound Med"},{"key":"pone.0306595.ref051","doi-asserted-by":"crossref","first-page":"965120","DOI":"10.3389\/fimmu.2022.965120","article-title":"Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy","volume":"13","author":"L Yin","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"pone.0306595.ref052","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ultrasmedbio.2009.12.004","article-title":"Dendritic cells loaded with ultrasound-ablated tumour induce in vivo specific antitumour immune responses","volume":"36","author":"J Deng","year":"2010","journal-title":"Ultrasound Med Biol"},{"issue":"10","key":"pone.0306595.ref053","first-page":"3877","article-title":"Infiltration by macrophages and lymphocytes in transplantable mouse sarcoma after irradiation with high-intensity focused ultrasound","volume":"29","author":"S Chida","year":"2009","journal-title":"Anticancer Res"},{"issue":"11","key":"pone.0306595.ref054","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.ultrasmedbio.2022.06.017","article-title":"Low-Intensity Focused Ultrasound Produces Immune Response in Pancreatic Cancer","volume":"48","author":"JB Joiner","year":"2022","journal-title":"Ultrasound Med Biol"},{"issue":"2","key":"pone.0306595.ref055","doi-asserted-by":"crossref","first-page":"e001008","DOI":"10.1136\/jitc-2020-001008","article-title":"Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity","volume":"8","author":"ND Sheybani","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"pone.0306595.ref056","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ultrasmedbio.2018.10.002","article-title":"Enhancing Checkpoint Inhibitor Therapy with Ultrasound Stimulated Microbubbles","volume":"45","author":"S Bulner","year":"2019","journal-title":"Ultrasound Med Biol"},{"issue":"5","key":"pone.0306595.ref057","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/cas.13578","article-title":"Sonodynamic therapy-assisted immunotherapy: A novel modality for cancer treatment","volume":"109","author":"Q Zhang","year":"2018","journal-title":"Cancer Sci"},{"issue":"1","key":"pone.0306595.ref058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-021-03807-6","article-title":"Sonodynamic therapy for gliomas","volume":"156","author":"A Bunevicius","year":"2022","journal-title":"J Neurooncol"},{"issue":"1","key":"pone.0306595.ref059","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41467-019-09760-3","article-title":"Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice","volume":"10","author":"W Yue","year":"2019","journal-title":"Nat Commun"},{"issue":"9","key":"pone.0306595.ref060","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"F Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"pone.0306595.ref061","doi-asserted-by":"crossref","first-page":"101370","DOI":"10.1016\/j.beem.2019.101370","article-title":"New insight in endocrine-related adverse events associated to immune checkpoint blockade","volume":"34","author":"G Elia","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4\u20135","key":"pone.0306595.ref062","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.seminoncol.2019.10.003","article-title":"A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients","volume":"46","author":"A Cortellini","year":"2019","journal-title":"Semin Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0306595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T17:23:07Z","timestamp":1720200187000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0306595"}},"subtitle":[],"editor":[{"given":"Niraj","family":"Babu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":62,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0306595","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]}}}